Sai Life Sciences Ltd IPO

Sai Life Sciences Ltd IPO

We are a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization. We provide end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities to global pharmaceutical innovators companies and biotechnology firms. We possess both (a) discovery / contract research and (b) chemistry, manufacturing, and control / contract development and manufacturing organization capabilities. We have research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India.

Sai Life Sciences Ltd IPO Details

Total Shares Offered

₹ 5,54,21,123

Offer to Public

3,81,16,934

Retail Max (Shares)

₹ 1,93,97,393

Pre Issue Promoters Holding

₹ 7,97,48,670

Exchange

BSE

Issue size

₹ 3042.62 Cr

IPO Open Date

Dec 11, 2024

Close Date

Dec 13, 2024

Lot Size

27

Min Investment

₹ 14,094

Issue Type

Book Building

Listing Date

Dec 18, 2024

Sai Life Sciences Ltd IPO Dates

check-icon
Dec 11, 2024
Opening date
check-icon
Dec 13, 2024
Closing date
check-icon
Dec 16, 2024
Basis of Allotment
check-icon
Dec 17, 2024
Initiation of Refunds
check-icon
Dec 17, 2024
Credit of Shares
check-icon
Dec 18, 2024
Listing date

Details

SectorType
SectorPharmaceuticals - Indian - Formulations
Sub SectorNA
Issue TypeBook Building

Subscription Status

*Values are in Lakhs

Investor Type

QIB

NII

Retail

Employee

Total

Sai Life Sciences Ltd Financial Status

Income Statement

Particulars (In Rs. Crores)

Balance Sheet

Particulars (In Rs. Crores)
Particulars (in Rs. Crores)FY23FY22FY21
Revenue from operations1,694.571,465.181,217.14
EBITDA483.78343.43208.23
PAT173.4695.2324.24
Total Assets1,546.231,002.281,006.34
Share Capital20.8418.0518.01
Total Borrowings745.711,215.571,210.27
Operating Activities (Net Cash)299.49202.44112.01
Investing Activities (Net Cash)-10.28-26.63-70.73
Financing Activities (Net Cash)745.711,215.571,210.27
Net Cashflow457.96152.0080.02

About Sai Life Sciences Ltd

Our Company was originally incorporated as `Sai Dru Syn Laboratories Limited' at Hyderabad, Telangana (Erstwhile Andhra Pradesh) as a public Limited Company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Our Company received the certificate of commencement of business from Registrar of Companies, Andhra Pradesh at Hyderabad on February 17, 1999. Subsequently, the name of our Company was changed from `Sai Dru Syn Laboratories Limited' to `Sai Life Sciences Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on December 11, 2003 and a fresh certificate of incorporation dated December 16, 2003 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Thereafter, the name of the Company was changed from `Sai Life Sciences Limited' to `Sai Advantium Pharma Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on August 16, 2006 and a fresh certificate of incorporation dated August 30, 2006 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of our Company was changed from `Sai Advantium Pharma Limited' to its present name, `Sai Life Sciences Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on April 20, 2012 and a fresh certificate of incorporation dated May 28, 2012 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.

The global small molecule contract research, development and manufacturing organization industry is forecasted to reach US$159 billion by 2028 (comprising approximately 53% of the overall global contract research, development and manufacturing organization industry), driven by increasing pharmaceutical and biotech research & development outsourcing, continued demand for small molecules and growing demand for cost-effective drugs. The Indian contract research, development and manufacturing organization market was among the fastest growing markets in Asia Pacific region over 2018-2023. The Indian market is projected to grow by 14.0% between 2023 and 2028, reaching an estimated value of US$14.1 billion in 2028. Revenue Model of the Company: Our fee arrangement is primarily based on two types of models: (i) fee-for-service (FFS) model and (ii) full-time equivalent (FTE) model. As of September 30, 2024, 35.40% and 64.60% of our contracts with customers are based on FFS model and FTE model, respectively. (i) FTE Model: Through FTE contracts, we offer services to our customers with dedicated resources. We execute work based on our customers' scope and bill for the number of resources engaged along with pass through costs on monthly basis. (ii) FFS Model Under the FFS model, we work based on purchase orders as well as long-term supply agreements with our customers to manufacture and deliver APIs or intermediates as per their requirements over multi-year periods. We also take on projects to produce and deliver specified quantities of materials as required by our customers. Furthermore, the table below sets forth the revenue split between our CRO and CDMO services, including as a percentage of our revenue from contract research, development and manufacturing activities, for the periods indicated.

We are a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization. We provide end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities to global pharmaceutical innovators companies and biotechnology firms. We possess both (a) discovery / contract research and (b) chemistry, manufacturing, and control / contract development and manufacturing organization capabilities. We have research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India.

Peer Comparison:

  • Divi's Laboratories Ltd
  • Suven Pharmaceuticals Ltd
  • Syngene International Ltd

Sai Life Sciences Ltd Key Points

Strengths

One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024, acting as a one-stop platform for discovery, development and manufacturing.

CDMO platform with a diverse mix of commercial and under-development molecules.

Fast-growing, integrated Discovery capabilities with focus on biology, chemistry and DMPK services.

Long-standing relationship with a diverse base of existing and new customers.

Modern R&D infrastructure with a differentiated delivery model and strong regulatory track-record.

Risk

Its financial performance depends on the company's ability to secure business from biotechnology and pharmaceutical customers and consequently its may be subject to risks, uncertainties and trends that affect the company customers in these industries over which the company has no control.

Its business may be adversely affected by a failures to develop or manufacture commercially viable drugs, including for reasons that are not within the company control.

The company may not be able to continue to serve its customers if the company fails to meet their standards in audits and inspections and this could significantly harm its reputation and result in the termination of ongoing projects by its customers.

Strategy

Increase cross-selling with existing customers and win new customers.

Continue to build a strong commercial development and manufacturing portfolio of CMC capabilities.

Pursue more integrated Discovery projects to drive customer stickiness along with larger integrated Discovery programs.

Continue to expand our existing capacity and add new technical capabilities.

Continue to drive operational excellence initiatives to improve profitability and return metrics.

How To Apply for Sai Life Sciences Ltd IPO Online?

Step 1:

Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

FAQs on IPO (Initial Public Offering)

What is the issue size of the Sai Life Sciences Ltd IPO?

close
Sai Life Sciences Ltd's IPO offers shares for up to 950 It begins on Dec 11, 2024 and ends on Dec 13, 2024.

What is the price of the Sai Life Sciences Ltd IPO?

close
The price of Sai Life Sciences Ltd IPO ranges between ₹522 to ₹549 per share.

What are the open and close dates for the Sai Life Sciences Ltd IPO?

close
The Sai Life Sciences Ltd IPO opens on Dec 11, 2024 and closes on Dec 13, 2024.

When will the Sai Life Sciences Ltd IPO be allotted?

close
The allotment for the Sai Life Sciences Ltd IPO will be finalised on Dec 16, 2024. The shares will be listed on BSE and NSE on Dec 18, 2024.

What is the minimum lot size required for Sai Life Sciences Ltd IPO?

close
The minimum lot size for Sai Life Sciences Ltd IPO is 27 shares, priced between ₹522 to ₹549 per share.

What is the GMP of Sai Life Sciences Ltd IPO?

close
The GMP (Grey Market Premium) of Sai Life Sciences Ltd IPO fluctuates based on market demand and sentiment.

How do you check the allotment status of Sai Life Sciences Ltd IPO?

close
To check the allotment status of Sai Life Sciences Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

Where is the Sai Life Sciences Ltd IPO getting listed?

close
The Sai Life Sciences Ltd IPO is getting listed on the BSE and NSE. Bidding opens on Dec 11, 2024, and closes on Dec 13, 2024. The allotment is finalised on Dec 16, 2024.

How do you apply for the Sai Life Sciences Ltd IPO?

close
To apply for the Sai Life Sciences Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions